- Home
- KTTA vs CANF Comparison
KTTA vs CANF Comparison
Compare KTTA & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- CANF
- Stock Information
- Founded
- KTTA 2020
- CANF 1994
- Country
- KTTA United States
- CANF Israel
- Employees
- KTTA N/A
- CANF N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- CANF Health Care
- Exchange
- KTTA Nasdaq
- CANF Nasdaq
- Market Cap
- KTTA 5.5M
- CANF 13.5M
- IPO Year
- KTTA 2021
- CANF N/A
- Fundamental
- Price
- KTTA $0.68
- CANF $1.03
- Analyst Decision
- KTTA
- CANF Strong Buy
- Analyst Count
- KTTA 0
- CANF 2
- Target Price
- KTTA N/A
- CANF $14.00
- AVG Volume (30 Days)
- KTTA 142.8K
- CANF 146.4K
- Earning Date
- KTTA 08-12-2025
- CANF 08-29-2025
- Dividend Yield
- KTTA N/A
- CANF N/A
- EPS Growth
- KTTA N/A
- CANF N/A
- EPS
- KTTA N/A
- CANF N/A
- Revenue
- KTTA N/A
- CANF $674,000.00
- Revenue This Year
- KTTA N/A
- CANF $461.72
- Revenue Next Year
- KTTA N/A
- CANF N/A
- P/E Ratio
- KTTA N/A
- CANF N/A
- Revenue Growth
- KTTA N/A
- CANF N/A
- 52 Week Low
- KTTA $0.67
- CANF $0.98
- 52 Week High
- KTTA $7.50
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- KTTA 32.67
- CANF 43.30
- Support Level
- KTTA $0.67
- CANF $1.00
- Resistance Level
- KTTA $0.77
- CANF $1.09
- Average True Range (ATR)
- KTTA 0.04
- CANF 0.03
- MACD
- KTTA 0.01
- CANF 0.00
- Stochastic Oscillator
- KTTA 14.02
- CANF 45.00
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).